BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29288421)

  • 41. Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review.
    Cencini E; Fabbri A; Lauria F; Bocchia M
    Ann Hematol; 2018 May; 97(5):821-829. PubMed ID: 29340761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
    Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
    Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
    Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
    Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
    [No Abstract]   [Full Text] [Related]  

  • 45. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
    Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
    Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Kalpadakis C; Pangalis GA; Dimopoulou MN; Vassilakopoulos TP; Kyrtsonis MC; Korkolopoulou P; Kontopidou FN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Tsaftaridis P; Plata E; Angelopoulou MK
    Hematol Oncol; 2007 Sep; 25(3):127-31. PubMed ID: 17514771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
    Luminari S; Goldaniga M; Cesaretti M; Orsucci L; Tucci A; Pulsoni A; Salvi F; Arcaini L; Carella AM; Tedeschi A; Pinto A; Stelitano C; Baldini L
    Leuk Lymphoma; 2016; 57(4):880-7. PubMed ID: 26379040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.
    Robinson AC; Nachar VR
    J Oncol Pharm Pract; 2020 Jul; 26(5):1248-1253. PubMed ID: 31766968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
    Liu Z; Markham M; Mandernach MW
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
    Wu L; Tian C; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
    Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
    Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of splenic marginal zone lymphoma.
    Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
    Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
    Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
    Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
    Thieblemont C
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):371-378. PubMed ID: 29222281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
    Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
    Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
    [No Abstract]   [Full Text] [Related]  

  • 56. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Massive intrafollicular and arterial hyalinosis of the spleen following rituximab and methylprednisolone therapy in a patient with splenic marginal zone lymphoma.
    Schaefer IM; Marx A; Sauer C; Hohloch K; Ghadimi BM; Trümper L; Ströbel P
    Histopathology; 2013 Mar; 62(4):664-7. PubMed ID: 23379885
    [No Abstract]   [Full Text] [Related]  

  • 58. Hyperhemolysis associated with marginal zone lymphoma.
    Yan M; Callum J; Lin Y
    Leuk Lymphoma; 2015 Mar; 56(3):829-31. PubMed ID: 24991717
    [No Abstract]   [Full Text] [Related]  

  • 59. Surgical management of splenic marginal zone lymphoma.
    Kennedy ND; Lê GN; Kelly ME; Harding T; Fadalla K; Winter DC
    Ir J Med Sci; 2018 May; 187(2):343-347. PubMed ID: 29043543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.